ClinicalTrials.gg
Active, not recruitingNCT06501976Updated Jun 16, 2026

An Exploratory Study of Lurbinectedin With Radiotherapy in SCLC With Single-lesion Progression After First Course Treatment

A Phase 2 interventional study of Lurbinectedin and Radiation Therapy in Small Cell Lung Carcinoma, sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-06-16.

Sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
9
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies testing PM 01183 in Small Cell Lung Carcinoma — 9 open to participants now, 11 under way, 3 of them phase 3. PM 01183 · Small Cell Lung Carcinoma.

Planned enrollment
15th of 16
9 · median 69
Started
2025
with 1 other
Phase 2
6 of 16
5 open now
Primary completion
2026-12
later than 2 of 10 live
Registered
11th of 16
by date
Lead sponsor
1 of 16
Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Among the 16 studies testing PM 01183 in Small Cell Lung Carcinoma, this one is the 15th largest by planned enrollment, is one of 2 that started in 2025, is one of 6 in phase 2, reaches primary completion later than 2 of the 10 other live ones, and was the 11th registered.

Small Cell Lung Carcinoma

1,303 studies on the registry are indexed under Small Cell Lung Carcinoma; 365 are open to participants now.

Browse Small Cell Lung Carcinoma studies →

Open to participants now

9 of the 16 studies testing PM 01183 in Small Cell Lung Carcinoma are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About PM 01183

PM 01183: first FDA approval 2020 (ZEPZELCA), first EMA approval 2026. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 265 Small Cell Lung Carcinoma studies recruiting now, 176 (66%) set no upper age limit and 65 (25%) stop at 75 or younger; 3 take children under 18; 8 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing PM 01183 in Small Cell Lung Carcinoma, or all of them as a file.
02

Study summary

This exploratory trial aims to determine if it is safe to use radiotherapy and lurbinectedin to treat SCLC with Single-lesion progression after first course treatment. Lurbinectedin kills tumor cells by blocks transcription and damages the deoxyribonucleic acid (DNA) of tumor cells, which is similar to the way radiation kills tumor cells. Traditional chemotherapy and radiotherapy is a routine medical treatment for locally-advanced SCLC, but the combination is always toxic. This trial may help understand if treating patients with lurbinectedin and radiotherapy could cause less side effects.

Read the detailed description

PRIMARY OBJECTIVE:

To describe the safety in terms of radiation therapy (RT) in combination with lurbinectedin in SCLC patients with Single-lesion progression after first course treatment.

SECONDARY OBJECTIVES:

To evaluate the preliminary efficacy of RT plus lurbinectedin, as assessed by Progression free survival (PFS) and Overall survival (OS).

OUTLINE:

Patients receive 2 cycles of lurbinectedin combined with radiotherapy followed by lurbinectedin alone. Patients receive lurbinectedin intravenously (IV) over 1 hour on day 1 of each cycle. G-CSF(Granulocyte Colony-Stimulating Factor) will be used for prophylaxis.

03

Conditions studied

  • Small Cell Lung Carcinoma

Keywords

  • Lurbinectedin
  • radiotherapy
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Has fully understood this study, voluntarily signed a written form, and is able to comply with the requirements and restrictions listed in the informed consent form;
  • Age ≥ 18 years, Male/female participants;
  • Has an (ECOG) performance status (PS) of 0 to 2;
  • With confirmed diagnosis of SCLC,with Single-lesion progression after first course treatment;
  • Has sufficient bone marrow, liver, kidney, and metabolic function, i.e., the functional levels of organs meet the following requirements:
  • (PLT) ≥ 100×10\^9/L;
  • (Hb) ≥ 90 g/L;
  • Absolute neutrophil (ANC) ≥ 2.0×10\^9/L;
  • Regardless of whether liver is present, (ALT) and aspartate aminotransferase (AST) ≤ 3.0× (ULN);
  • Alkaline phosphatase (ALP) ≤ 5×ULN;
  • Total (TBIL) ≤ 1.5×ULN, and direct bilirubin ≤ 1.0×ULN;
  • Serum creatinine ≤ 1.5×ULN or rate ≥ 30 mL/min (calculated using the Cockcroft-Gault formula);
  • Creatine phosphokinase (CPK) ≤ 2.5×ULN;
  • Albumin ≥ 3.0 g/dL.
  • A female of (FCBP) must have a negative serum pregnancy test prior to study entry. Woman of childbearing potential (WOCBP) must use adequate during the test drug treatment period and for 6 months after the final dose. Male patients (with partners of WOCBP) must use adequate contraception for the duration of study participation, and 4 months after completion of administration.

Exclusion criteria

Exclusion Criteria:

  • With concurrent , a history of spinal cord compression, or meningeal ;
  • Patients with obstructive atelectasis, superior vena cava syndrome requiring surgical/ endoscopic/ interventional treatment; suspected or confirmed pulmonary embolism patients; those with uncontrollable large amounts of pleural effusion, ascites, or pericardial effusion;
  • Patients known to be allergic to any component of the test drug;
  • Pregnancy or breastfeeding or who has a positive serum pregnancy test;
  • Comorbidities Requirements:

    1. Has unstable angina, myocardial infarction, congestive heart failure (CHF) classified as (NYHA) II or higher, or other cardiovascular diseases currently or within the past year prior to screening;
    2. Patients with uncontrolled hypertension (systolic blood pressure greater than 160 mmHg and/or diastolic blood pressure greater than 100 mmHg), or a history of hypertensive crisis or hypertensive encephalopathy;
    3. Patients with severe arrhythmias requiring medication;
    4. Patients with active infections requiring systemic antibacterial, antifungal, or antiviral treatment within 2 weeks prior to administration;
    5. Patients with evidence of bleeding tendencies or coagulation disorders;
    6. Patients with other significant diseases judged unsuitable for entry by the investigator.
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
9 participants (estimated)

Study arms

  • Experimental
    Experimental Treatment: Lurbinectedin combined with Radiotherapy

    Patients receive 2 cycles of lurbinectedin 3.2 mg/m2 combined with radiotherapy followed by lurbinectedin 3.2 mg/m2 alone. Patients receive lurbinectedin intravenously (IV) over 1 hour on day 1 of each cycle.

    Drug: Lurbinectedin · Radiation: Radiation Therapy

Interventions

  • DrugPM 01183Studies of PM 01183PM 01183 pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    2.6 mg/m2 , Given IV, every 21 days

    Also known as: PM01183, Zepzelca

  • RadiationRadiation Therapy

    Thoracic radiotherapy

06

What researchers measure

Primary outcomes

  1. Incidence of adverse events of radio therapy with lurbinectedin

    ≥grade 4 treatment related adverse events within 30 days of final RT fraction; Any treatment related adverse events leading to dose delays or reductions of lurbinectedin; Any treatment related serious adverse events .

    Time frame: 30 days following treatment completion

Secondary outcomes

  1. Progression free survival (PFS)

    PFS will be estimated using the Kaplan-Meier method, and a 95% confidence interval for median PFS will be estimated.

    Time frame: From protocol treatment initiation to disease progression or death, assessed up to 24 months

  2. Overall survival (OS)

    OS will be estimated using the Kaplan-Meier method, and a 95% confidence interval for median OS will be estimated.

    Time frame: From treatment initiation to death, , assessed up to 24 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2025 (actual). Primary completion is estimated for Dec 2026, 12 months after the start.

Of 150 non-industry phase 2 interventional studies under Small Cell Lung Carcinoma, half reached primary completion within 53 months of starting (the median), counting those still running; a quarter within 36 and three quarters within 87. This study's planned 12 months is below that.

Counting every sponsor, half of 204 studies reached it within 46 months; a quarter within 29 and three quarters within 84.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 29, 2024
First posted
Jul 15, 2024
StartActual
Dec 31, 2025
Primary completionEst.
Dec 2026
CompletionEst.
Jun 2027
Last update
Jun 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 16, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06501976
Responsible party
Sponsor
First posted
Jul 15, 2024
Start date
Dec 31, 2025
Primary completion
Dec 2026 (estimated)
Completion
Jun 2027 (estimated)
Last update
Jun 16, 2026

Study contacts

Nan Bi, MD
principal investigator · Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PM 01183

Start the discussion